Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". (February 2021)

• Record Type: Journal Article
• Authors: Schneeweiss, Andreas; Ettl, Johannes; Lüftner, Diana; Beckmann, Matthias W.; Belleville, Erik; Fasching, Peter A.; Fehm, Tanja N.; Geberth, Matthias; Häberle, Lothar; Hadji, Peyman; Hartkopf, Andreas D.; Hielscher, Carsten; Huober, Jens; Ruckhäberle, Eugen; Janni, Wolfgang; Kolberg, Hans Christian; Kurbacher, Christian M.; Klein, Evelyn; Lux, Michael P.; Müller, Volkmar; Nabieva, Naiba; Overkamp, Friedrich; Tesch, Hans; Laakmann, Elena; Taran, Florin-Andrei; Seitz, Julia; Thomssen, Christoph; Untch, Michael; Wimberger, Pauline; Wuerstlein, Rachel; Volz, Bernhard; Wallwiener, Diethelm; Wallwiener, Markus; Brucker, Sara Y.;
• Is Part Of: Breast. Volume 55(2021)
• Page Start: 138
• Page End: 139
• Publication Date: 2021-02
• Subjects: Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2020.12.007
• Languages: English
• ISSNs: 0960-9776